| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8dc1442e8263a086103a8b2a6b9753f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_715dc3e6aff9d053f8b8585719bad345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17521019463cf7a6cf3508f75ef70f63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d47418ded1752105c44a3876c09c5631 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2013-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_141aeae3ba27f0a2f0653f701dd78d7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6feb216cedeec0d739b8a8568833cde9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f06e3909202a600c704afe936fca911 |
| publicationDate |
2014-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2812434-A1 |
| titleOfInvention |
Agonists and antagonists of toll-like receptor (tlr) 13 |
| abstract |
The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids. |
| priorityDate |
2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |